Eszopiclone – benefits map Review article
Article Sidebar
Published:
Jun 30, 2025
Keywords:
insomnia, eszopiclone, sedative-hypnotic drugs
Main Article Content
Abstract
Eszopiclone is a modern non-benzodiazepine GABA-A receptor agonist used for the treatment of insomnia, characterized by a favorable efficacy and safety profile. Compared to traditional hypnotics, it offers a rapid onset of action, prolongation of total sleep time, and improvement in sleep quality, with minimal risk of dependence or adverse effects. One of its key advantages is sustained effectiveness during long-term use without significant tolerance. Eszopiclone has also been shown to improve daytime functioning and overall quality of life in patients with chronic insomnia. This article presents the main therapeutic benefits of eszopiclone, supported by clinical evidence, and discusses its role in current treatment guidelines for sleep disorders.
Article Details
How to Cite
Dudek, D. (2025). Eszopiclone – benefits map. Medycyna Faktow (J EBM), 18(2(67), 247-251. https://doi.org/10.24292/01.MF.0225.12
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Riemann D, Baglioni C, Bassetti C et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017; 26: 675-700.
2. Kyle SD, Morgan K, Espie CA. Insomnia and health-related quality of life. Sleep Med Rev. 2010; 14: 69-82.
3. Sofi F, Cesari F, Casini A et al. Insomnia and risk of cardiovascular disease: a meta-analysis. Eur J Prev Cardiol. 2014; 21: 57-64.
4. Buysse DJ. Sleep health and the risk for chronic disease: conceptual and practical implications. Sleep Health. 2023; 9(1): 10-8.
5. Baglioni C, Battagliese G, Feige B et al. Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011; 135: 10.
6. Zhang J, He M, Wang X et al. Association of sleep duration and risk of mental disorder: a systematic review and meta-analysis. Sleep Breath. 2024; 28(1): 261-80.
7. Jarema M, Wichniak A. Eszopiclone in the treatment of insomnia. Farmakoterapia w Psychiatrii i Neurologii. 2020; 36(1): 9-21.
8. American Sleep Disorder Association (ASDA). The international classification of sleep disorders: diagnostic and coding manual. Lawrence, Allen, 1990.
9. Wilson S, Anderson K, Baldwin D et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. J Psychopharmacol. 2019; 33(8): 923-47.
10. Wichniak A, Wierzbicka A, Jarema M. Leczenie bezsenności – wpływ trazodonu i leków nasennych na sen. Psychiatr Pol. 2021; 55(4): 743-55.
11. Wichniak A, Bieńkowski P, Dudek D et al. Stanowisko Polskiego Towarzystwa Psychiatrycznego w sprawie stosowania pochodnych benzodiazepiny i leków o podobnym mechanizmie działania w leczeniu zaburzeń psychicznych. Psychiatr Pol. 2023; 57(4): 873-5.
12. Wichniak A, Bieńkowski P, Dąbrowski R et al. Leczenie bezsenności osób w starszym wieku. Zalecenia Polskiego Towarzystwa Badań nad Snem, Polskiego Towarzystwa Medycyny Rodzinnej i Polskiego Towarzystwa Psychiatrycznego. Psychiatr Pol. 2023; 57(3): 495-516.
13. Lin FY, Chen PC, Liao CH et al. Retrospective population cohort study on hip fracture risk associated with zolpidem medication. Sleep. 2014; 37(4): 673-9.
14. Seppala LJ, Glind van de EMM, Daams JG et al. Fall-risk-increasing drugs: A systematic review and meta-analysis: III. Others. J Am Med Dir Assoc. 2018; 19(4): 372.e1-372.e8.
15. Tom SE, Wickwire EM, Park Y et al. Nonbenzodiazepine sedative hypnotics and risk of fall-related injury. Sleep. 2016; 39(5): 1009-14.
16. Zheng X, He Y, Yin F et al. Pharmacological interventions for the treatment of insomnia: quantitative comparison of drug efficacy. Sleep Med. 2020; 72: 41-495.
17. Krystal AD, Walsh JK, Laska E et al. Sustained efficacy of eszopiclone over six months of nightly treatment: results of a randomized, double-blind, placebo controlled study in adults with chronic insomnia. Sleep. 2003; 26: 793-9.
18. Fava M, Schaefer K, Huang H et al. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry. 2011; 72(4): 473-9.
19. Charakterystyka produktu leczniczego Esogno. Esogno, 1 mg, tabletki powlekane; Esogno, 2 mg, tabletki powlekane; Esogno, 3 mg, tabletki powlekane.
20. Erman MK, Zammit G, Rubens R et al. A Polysomnographic Placebo-Controlled Evaluation of the Efficacy and Safety of Eszopiclone Relative to Placebo and Zolpidem in the Treatment of Primary Insomnia. J Clin Sleep Med. 2008; 4(3): 229-34.
2. Kyle SD, Morgan K, Espie CA. Insomnia and health-related quality of life. Sleep Med Rev. 2010; 14: 69-82.
3. Sofi F, Cesari F, Casini A et al. Insomnia and risk of cardiovascular disease: a meta-analysis. Eur J Prev Cardiol. 2014; 21: 57-64.
4. Buysse DJ. Sleep health and the risk for chronic disease: conceptual and practical implications. Sleep Health. 2023; 9(1): 10-8.
5. Baglioni C, Battagliese G, Feige B et al. Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011; 135: 10.
6. Zhang J, He M, Wang X et al. Association of sleep duration and risk of mental disorder: a systematic review and meta-analysis. Sleep Breath. 2024; 28(1): 261-80.
7. Jarema M, Wichniak A. Eszopiclone in the treatment of insomnia. Farmakoterapia w Psychiatrii i Neurologii. 2020; 36(1): 9-21.
8. American Sleep Disorder Association (ASDA). The international classification of sleep disorders: diagnostic and coding manual. Lawrence, Allen, 1990.
9. Wilson S, Anderson K, Baldwin D et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. J Psychopharmacol. 2019; 33(8): 923-47.
10. Wichniak A, Wierzbicka A, Jarema M. Leczenie bezsenności – wpływ trazodonu i leków nasennych na sen. Psychiatr Pol. 2021; 55(4): 743-55.
11. Wichniak A, Bieńkowski P, Dudek D et al. Stanowisko Polskiego Towarzystwa Psychiatrycznego w sprawie stosowania pochodnych benzodiazepiny i leków o podobnym mechanizmie działania w leczeniu zaburzeń psychicznych. Psychiatr Pol. 2023; 57(4): 873-5.
12. Wichniak A, Bieńkowski P, Dąbrowski R et al. Leczenie bezsenności osób w starszym wieku. Zalecenia Polskiego Towarzystwa Badań nad Snem, Polskiego Towarzystwa Medycyny Rodzinnej i Polskiego Towarzystwa Psychiatrycznego. Psychiatr Pol. 2023; 57(3): 495-516.
13. Lin FY, Chen PC, Liao CH et al. Retrospective population cohort study on hip fracture risk associated with zolpidem medication. Sleep. 2014; 37(4): 673-9.
14. Seppala LJ, Glind van de EMM, Daams JG et al. Fall-risk-increasing drugs: A systematic review and meta-analysis: III. Others. J Am Med Dir Assoc. 2018; 19(4): 372.e1-372.e8.
15. Tom SE, Wickwire EM, Park Y et al. Nonbenzodiazepine sedative hypnotics and risk of fall-related injury. Sleep. 2016; 39(5): 1009-14.
16. Zheng X, He Y, Yin F et al. Pharmacological interventions for the treatment of insomnia: quantitative comparison of drug efficacy. Sleep Med. 2020; 72: 41-495.
17. Krystal AD, Walsh JK, Laska E et al. Sustained efficacy of eszopiclone over six months of nightly treatment: results of a randomized, double-blind, placebo controlled study in adults with chronic insomnia. Sleep. 2003; 26: 793-9.
18. Fava M, Schaefer K, Huang H et al. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry. 2011; 72(4): 473-9.
19. Charakterystyka produktu leczniczego Esogno. Esogno, 1 mg, tabletki powlekane; Esogno, 2 mg, tabletki powlekane; Esogno, 3 mg, tabletki powlekane.
20. Erman MK, Zammit G, Rubens R et al. A Polysomnographic Placebo-Controlled Evaluation of the Efficacy and Safety of Eszopiclone Relative to Placebo and Zolpidem in the Treatment of Primary Insomnia. J Clin Sleep Med. 2008; 4(3): 229-34.